FY2025 · ended Dec 31, 2025 · Revenue $3.22B, +12.9% YoY · Filed Feb 26, 2026
BioMarin Pharmaceutical Inc (BMRN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.2 billion and net income of $348.9 million. Free cash flow was $725.0 million. As of Sep 30, 2026 it held $736.0 million in cash and investments and $4.2 billion in total debt.
Revenue (TTM)
$3.66B
+18.1% vs year-ago TTM
Net income (TTM)
$-19.11M
-103.7% vs year-ago TTM
Operating cash flow (TTM)
$676.62M
-26.0% vs year-ago TTM
Free cash flow (TTM)
$557.86M
-33.0% vs year-ago TTM
EPS (TTM)
$-0.10
-103.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
192.32M
+0.8% vs prior year
Net cash
$-3.44B
as of Sep 30, 2026
Operating margin
3.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Novato, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1048477
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M | -$82.3M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | -$64.1M |
| Diluted EPS | $1.80 | $2.21 | $0.87 | $0.75 | -$0.35 |
| Operating cash flow | $828.0M | $572.8M | $159.3M | $175.9M | $304.5M |
| Free cash flow | $725.0M | $487.4M | $62.6M | $54.9M | $209.0M |
| Total assets | $7.6B | $7.0B | $6.8B | $6.4B | $6.0B |
| Total liabilities | $1.5B | $1.3B | $1.9B | $1.8B | $1.7B |
| Stockholders' equity | $6.1B | $5.7B | $5.0B | $4.6B | $4.3B |
| Cash and investments | $2.1B | $1.7B | $1.7B | $1.6B | $1.5B |
| Total debt | $45.7M | $38.8M | $46.9M | $36.9M | $44.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 30, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 14, 2026 | Sep 10, 2026 |
All 1000 BioMarin Pharmaceutical Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.